Analyst Reco. Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq Other stock markets 04:15:00 2024-05-03 pm EDT			5-day change	1st Jan Change
1.51 ^USD	+4.14%		+7.47%	-86.11%

Apr. 17	Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	MT
Apr. 16	Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	Apr. 17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	Apr. 16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	Apr. 16	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	Jan. 03	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $25 From $32, Maintains Buy Rating	Nov. 08	MT
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier	23-09-20	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $32 From $42, Maintains Buy Rating	23-08-11	MT
Ladenburg Thalmann Adjusts Price Target on Marinus Pharmaceuticals to $13 From $17, Maintains Buy Rating	23-08-11	MT
Oppenheimer Downgrades Marinus Pharmaceuticals to Perform From Outperform, Adjusts Price Target to $9 From $14	23-08-11	MT
Baird Adjusts Price Target on Marinus Pharmaceuticals to $20 From $24, Keeps Outperform Rating	23-08-11	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $20 From $21, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Truist Adjusts Price Target on Marinus Pharmaceuticals to $42 From $50, Keeps Buy Rating	23-05-12	MT
RBC Lowers Price Target on Marinus Pharmaceuticals to $21 From $22, Maintains Outperform, Speculative Risk	23-05-12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $14 From $12, Maintains Outperform Rating	23-04-25	MT
JMP Securities Adjusts Price Target on Marinus Pharmaceuticals to $18 From $19, Maintains Market Outperform Rating	23-03-08	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $22 From $23, Maintains Outperform, Speculative Risk	23-03-08	MT
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating	23-01-23	MT
RBC Initiates Marinus Pharmaceuticals at Outperform, Speculative Risk, Sets Price Target at $23	23-01-20	MT
Baird Lowers Price Target on Marinus Pharmaceuticals to $24 From $32, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $12 From $23, Maintains Outperform Rating	22-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Analyst Reco.

Filters